34624-38-9

Basic information

• Product Name: 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE
• Synonyms: 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE;3-METHOXYPHENYL ACETIC ACID HYDRAZIDE;3-Methoxyphenylacetic acid hydrazide 97%;Benzeneacetic acid,3-methoxy-, hydrazide;2-(3-methoxyphenyl)ethanehydrazide;3-Methoxyphenylaceticacidhydrazide97%
• CAS NO: 34624-38-9
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.2
• Mol File: 34624-38-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 89 °C
• Boiling Point: 402.6°Cat760mmHg
• Flash Point: 197.3°C
• Appearance: /
• Density: 1.156g/cm³
• Vapor Pressure: 1.08E-06mmHg at 25°C
• Refractive Index: 1.549
• PKA: 13.03±0.18(Predicted)
• CAS DataBase Reference: 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE(34624-38-9)
• EPA Substance Registry System: 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE(34624-38-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 34624-38-9(Hazardous Substances Data)

Usage

General Description

2-(3-Methoxyphenyl)ethanohydrazide is a compound with the chemical formula C9H12N2O2. It is a hydrazine derivative with a structure consisting of a phenyl ring with a methoxy group and an ethanohydrazide moiety. 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE has been studied for its potential pharmaceutical applications, including its role as an antitubercular agent. Its chemical structure and properties make it a candidate for further research in drug development and discovery. Additionally, the compound may have potential uses in other fields such as organic synthesis and medicinal chemistry.

InChI:InChI=1/C9H12N2O2/c1-13-8-4-2-3-7(5-8)6-9(12)11-10/h2-5H,6,10H2,1H3,(H,11,12)

Upstream product

• 18927-05-4 methyl (3-methoxyphenyl)acetate 
• 1798-09-0 m-methoxyphenylacetic acid 
• 35553-92-5 ETHYL 3-METHOXYPHENYLACETATE 
• 6834-42-0 3-methoxyphenylacetic acid chloride 

Downstream Products

• 34547-01-8 5-(3-methoxy-benzyl)-3H-[1,3,4]oxadiazol-2-one 
• 436155-40-7 methyl 2-[2-(3-methoxyphenyl)acetyl]hydrazinecarboxylate 
• 858954-36-6 2-(3-methoxyphenyl)-N'-((1E)-{2-[(4-methylphenyl)sulfonyl]phenyl}methylene)acetohydrazide 
• 1082953-15-8 tert-butyl 5-[5-(3-methoxybenzyl)-1,3,4-oxadiazol-2-ylamino]indazole-1-carboxylate 
• 1082953-14-7 C₂₂H₂₅N₅O₄S 
• 1038304-53-8 4-amino-3-(3-methoxybenzyl)-1H-1,2,4-triazole-5(4H)-thione 
• 1394137-58-6 C₁₇H₁₃ClN₄OS 
• 1394137-59-7 C₁₇H₁₂F₂N₄OS 
• 1403568-80-8 4-(4-chlorophenyl)-1-(2-(3-methoxyphenyl)acetyl)thiosemicarbazide 
• 1403568-95-5 C₁₆H₁₄ClN₃OS 
• 1403568-97-7 C₁₇H₁₇N₃O₂S 
• 1403568-82-0 4-(4-methoxyphenyl)-1-(2-(3-methoxyphenyl)acetyl)thiosemicarbazide 
• 1403569-06-1 C₁₇H₁₇N₃O₂S 
• 1403568-89-7 4-(2-methoxyphenyl)-1-(2-(3-methoxyphenyl)acetyl)thiosemicarbazide 

Relevant articles and documents

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

Synthesis, in-vitro, in-vivo anti-inflammatory activities and molecular docking studies of acyl and salicylic acid hydrazide derivatives

Over the course of time several drugs have been synthesized and are available in market for the treatment of inflammation. However, they were unable to cure effectively and associated with side effects. To effectively deal with such diseases, heterocycles and their derivatives have gained their special position. For this reason 1,3,4-oxadiazole (15–16), 1,2,4-triazole (17–18), Schiff base (19–24) and 3,5-disubstituted pyrazole (25) derivatives were synthesized starting from salicylic acid and acyl acid hydrazides (12–14) as COX-1 and COX-2 inhibitors. In vivo anti-inflammatory activities were also tested by carrageenan-induced mice paw edema against albino mice of any sex. Structures of all the synthesized compounds were confirmed by FT-IR and 1H NMR analysis. Schiff base derivative of 4-amiontirazole (24) with IC50 value of 1.76 ± 0.05 (COX-2) and 117.8 ± 2.59 emerged as potent COX-2 inhibitor. Furthermore, we also performed in-vivo anti-inflammatory investigations by using carrageenan induced paw edema test. From in-vivo anti-inflammatory activities, it was found that after 1 h the maximum percentage inhibition 15.8% was observed by compound 14 which is comparable with that of the standard drug followed by the compound 18 with percentage inhibition of 10.5%. After 3 h, the maximum percentage inhibition was observed by compound 18 with 22.2% and compound 14 with 16.7%. After 5 h the maximum percentage inhibition was observed by compound 18 with 29.4% followed by compound 16 with 23.5%. We further explore the mechanism of the inhibition by using docking simulations. Docking studies revealed that the selective COX-2 inhibitors established interactions with additional COX-2 enzyme pocket residues.

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.